|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cilostazol for secondary stroke prevention:systematic review and meta-analysis显示文摘Background Stroke is one of the leading causes of death worldwide.Cilostazol,an antiplatelet and phosphodiesterase 3 inhibitor,has not been clearly established for ischaemic stroke use.We aim to determine the efficacy and safety of cilostazol for secondary stroke prevention.Methods MEDLINE,EMBASE,Cochrane Library,Web of Science and ClinicalTrials.gov were searched from inception to 25 September 2020,for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo,in patients with ischaemic stroke.Version 2 of the Cochrane risk-of-bias tool for randomised trials(RoB 2)was used to assess study quality.This meta-analysis was reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)statement.Results Eighteen randomised trials comprising 11429 participants were included in this meta-analysis.Most trials possessed low risk of bias and were of low heterogeneity.Cilostazol significantly reduced the rate of ischaemic stroke recurrence(risk ratio,RR=0.69,95%CI 0.58 to 0.81),any stroke recurrence(RR=0.64,95%CI 0.54 to 0.74)and major adverse cardiovascular events(RR=0.67,95%CI 0.56 to 0.81).Cilostazol did not significantly decrease mortality(RR=0.90,95%CI 0.64 to 1.25)or increase the rate of good functional outcome(Modified Rankin Scale score of 0–1;RR=1.07,95%CI 0.95 to 1.19).Cilostazol demonstrated favourable safety profile,significantly reducing the risk of intracranial haemorrhage(RR=0.46,95%CI 0.31 to 0.68)and major haemorrhagic events(RR=0.49,95%CI 0.34 to 0.70).Conclusions Cilostazol demonstrated superior efficacy and safety profiles compared with traditional antiplatelet regimens such as aspirin and clopidogrel for secondary stroke prevention but does not appear to affect functional outcomes.Future randomised trials can be conducted outside East Asia,or compare cilostazol with a wider range of antiplatelet agents. | Choon Han Tan Andrew GR Wu Ching-Hui Sia Aloysius ST Leow Bernard PL Chan Vijay Kumar Sharma Leonard LL Yeo Benjamin YQ Tan | 2021 | Stroke & Vascular Neurology2021，6，3： | 2 |
| 2 | Cecal ligation and puncture with total parenteral nutrition:a clinically relevant model of the metabolic,hormonal,and inflammatory dysfunction associated with critical illness显示文摘 | Heuer JG Bailey DL Sharma GR | 2004 | J Surg Res2004，121，2： | 1 |
| 3 | ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，3： | 1 |
| 4 | ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，3： | 1 |
| 5 | Spontaneous intmcystic hemorrhage of the arachnoid cyst: a case report and review of literature显示文摘 | Jha R Sharma GR Kumar P | 2008 | JNMA J Nepal Med Assoc2008，47，172： | 1 |
| 6 | ERCC1 expression is a predict or of survival in resected patients with nonsmall cell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，3： | 1 |
| 7 | ERCC1 expression is a predictor of survival in resected patients with non - small cell lung cancer 显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，3： | 1 |
| 8 | Reconstruction of a major abdominal and chest wall defect using latissimus dorsi and extended deep inferior epigastric artery flap显示文摘 | Sharma RK Verma GR Biswas G | 1992 | Ann Plast Surg1992，28，4： | 1 |
| 9 | History of materialsused for recording static and dynamic occlusal contact marks : aliterature review 显示文摘 | Sharma A Rahul GR Poduval ST | 2013 | J Clin Exp Dent2013，5，1： | 1 |
| 10 | Regulatory T cells suppressinnate immunity in kidney ischemia-reperfusion injury显示文摘 | Kinsey GR Sharma R Huang L | 2009 | J AmSoc Nephrol2009，20，8： | 1 |
| 11 | ERCC1 expression is a p redictor of survival in resected patients with non small cell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，3： | 1 |
| 12 | ERCC1 expression is a predictor of survival in resected patients with non-small-cell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，： | 1 |
| 13 | RECC1 expression is a predictor of survival in resected patients with non-small cell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，3： | 1 |
| 14 | ERCC1 express-ion is a predictor of survival in resected patients with non-small celllung cancer显示文摘 | Simon GR Sharma S Cantor A Smith P Bepler G | 2005 | Chest2005，127，3： | 1 |
| 15 | ERCC1 expression is a predictor of survival in resected patients with non-small-cell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，3： | 1 |
| 16 | ERCC1 expression is a predictor of survival in resected patients with non-smallcell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，： | 1 |
| 17 | ERCC1 expression is a predictor of survival in resected patients with non-small-cell lung cancer显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，127，： | 1 |
| 18 | ERCC1expressi-on is a predictor of survival in resected patients with non-small celllung cancer显示文摘 | Simon GR Sharma S Cantor A SmithP Bepler G | 2005 | Chest2005，127，3： | 1 |
| 19 | Effects of hyperglycemia and insulin therapy on outcome in a hyperglycemic septic model of critical illness显示文摘 | Heuer J Sharma GR Zhang T | 2006 | J Trauma2006，60，4： | 1 |
| 20 | ERCC1 expression is a predictor of survival in reseeted patients with non-small cell lung cancer 显示文摘 | Simon GR Sharma S Cantor A | 2005 | Chest2005，27，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员